BioLineRx Ltd BLRX - reported that it has signed a worldwide, exclusive license agreement with Genoscience and RFS Pharma to develop and commercialize BL-8030, an orally available treatment for Hepatitis C. According to a definitive agreement between the companies, Consolidated Communications Holdings will acquire all the outstanding shares of SureWest Communications - SURW - in a cash and stock transaction valued at $23.00 per share, or a total of approximately $340.9 million, exclusive of debt. Sparton Corp - SPA - reported that it has been awarded an approximately $7.6 million contract by Australia to manufacture the AN/SSQ-62E and AN/SSQ-53F sonobuoys. ********************************* THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! (Read Full Disclaimer at http://www.crwenewswire.com/disclaimer)

• Added by: karmastock
• Date added: 06/02/12
• Video Duration: 01:21
• Category: News
• Number of views:326
• Tags: Consolidated Communications, Genoscience, RFS Pharma, sonobuoys, BioLineRx, SureWest, Sparton, SPA, BLRX, SURW, Nasdaq:BLRX, NYSE:SPA, Nasdaq:SURW (SPA, BLRX, SURW) CRWENewswire Stocks In Action



Post a Comment

To add a comment, please fill out the box below and click on the submit button. Comment:

There are currently no comments for this video